The unique properties of Bacillus subtilis MM40® (DSM 21097; Budapest Treaty DSM 33619; EU Trademark No. 018279328) form the basis for six distinct research and application fields. Each field is supported by scientific data, clinical observations or findings from the published literature.
In a placebo-controlled, randomised study at Medicom In Medical Center, Dnipro (Vogel et al., April 2026), 72 adults were randomized; 70 completers entered the analysis. The primary endpoint was HOMA-IR as a measure of insulin resistance. The probiotic group showed a HOMA-IR reduction of 44 % (between p = 0.003), a fasting glucose reduction of 13 % (between p < 0.001), and an insulin reduction of 37 % (between p = 0.015) compared to placebo. Additional improvements were documented in CRP (−39 %) and the lipid profile.
These observations are to be viewed in the context of the scientific discussion regarding the connection between the gut microbiome and metabolic markers. The results are currently considered potentially relevant for research into metabolic syndrome.
Data originate from a single clinical study. Further research is required. These are not approved health claims under EU Regulation 1924/2006.
Within the same clinical study, a within-group reduction in zonulin levels of 16 % (within p = 0.0026) was observed in the probiotic group. The difference relative to placebo was not statistically significant (between-group p = 0.26). Zonulin is discussed in the scientific literature as a marker for intestinal barrier permeability; the within-group reduction observed here is to be interpreted as a mechanistic indicator of barrier support.
Furthermore, shifts in gut flora composition were documented, particularly in the Firmicutes to Bacteroidetes ratio. As a natural spore-former, B. subtilis MM40® is capable of surviving gastric transit and germinating in the intestinal environment - a process described in the scientific literature as relevant for microbiome interaction.
The described observations are based on a single clinical study and require confirmation through further research.
In in-vitro investigations at the University Medical Center Schleswig-Holstein (UKSH), Lübeck campus, inhibition zones of B. subtilis MM40® against selected reference organisms were documented. Among the tested organisms were methicillin-resistant Staphylococcus aureus (MRSA) and Proteus species.
The strain's ability to produce surfactin - a cyclic lipopeptide with biosurfactant properties - is investigated in the scientific literature as a potential mechanism for antimicrobial activity. These results serve as the basis for further research in the field of infection research.
In-vitro results are not directly transferable to human application. Clinical studies on antimicrobial efficacy are pending.
Documented at UKSH Lübeck
Spore-forming bacteria of the species Bacillus subtilis are the subject of extensive immunological research. The scientific literature describes that B. subtilis spores can interact with the GALT (Gut-Associated Lymphoid Tissue) - the intestine-associated lymphatic tissue.
This interaction is discussed in research as relevant for the modulation of gut-associated immune responses. The GALT harbours a substantial proportion of the body's immunologically active cells and thus represents a central interface between the gut microbiome and the immune system.
The specific immunomodulatory properties of MM40® are the subject of ongoing investigations and will be further evaluated in future studies.
Surfactin, a cyclic lipopeptide that can be produced by B. subtilis MM40®, possesses pronounced surface-active properties. In the dermatological literature, these properties are discussed as potentially relevant for skincare applications.
The antimicrobial properties of surfactin, which have been investigated in in-vitro studies, make it a subject of research in the field of cosmetic and dermatological formulations. The possibility of integrating surfactin into skincare products is currently being explored.
The described properties of surfactin are based on published research findings. Specific product formulations are in the development phase.
Surfactin as a natural biosurfactant with pronounced surface-active properties described in the literature.
In-vitro investigations into surfactin's antimicrobial properties as the basis for dermatological application research.
The integration of surfactin into skincare formulations is being explored as a subject of current research and development.
Changes in specific biomarkers observed in the clinical study - including fasting glucose, insulin and zonulin - are associated in the scientific literature with aspects of biological aging. The connection between metabolic health and the aging process is an active field of research.
The concept of "inflammaging" - the link between chronic low-grade inflammation and the aging process - is intensively investigated in microbiome research. The composition of the gut microbiome and its changes over the course of life are described as potential influencing factors on biological age.
The connections between observed biomarkers and biological aging are based on the published scientific literature. MM40® is not approved or marketed as an anti-aging product.
Metabolic markers observed in the study are linked in the literature to biological aging processes.
The connection between the microbiome, chronic inflammation and aging processes is a subject of current research.
Metabolic markers and biological age are described in the scientific literature as interconnected.
All information presented on this page is based on proprietary clinical study results, in-vitro investigations or the published scientific literature. The data serve exclusively for scientific information purposes and do not constitute approved health claims under EU Regulation 1924/2006 (Health Claims Regulation).
Further research is required for all described application fields. B. subtilis MM40® is not intended for the diagnosis, treatment or cure of diseases.
Learn more about the clinical data behind our platform technology or discover collaboration opportunities.
